| Browse All

Pharvaris N.V. (PHVS)

Healthcare | Biotechnology | Zug, Switzerland | NasdaqGS
28.58 USD -0.20 (-0.695%) ⇩ (April 17, 2026, 4 p.m. EDT)
After hours: 28.58

Short-term: ★★★☆☆ | Long-term: ★★☆☆☆ | Dividends: ☆☆☆☆☆
Hot Take | April 11, 2026, 3:14 p.m. EDT

PHVS is a high-risk, high-reward biotechnology stock with significant volatility and negative fundamentals. The recent price action shows some consolidation, but the stock has been in a downtrend. The options market indicates a cautious outlook with a focus on downside protection, suggesting that traders are wary of further declines. While there are positive analyst ratings, the stock's lack of dividends and weak earnings make it unsuitable for dividend-focused investors. Long-term investors should consider the potential for growth in the biotech sector, but the current fundamentals and market sentiment suggest a cautious approach.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
AutoTheta ✓0.029367
AutoETS0.029445
AutoARIMA0.029445
MSTL0.033913

Forecast horizon: 45 days | Selected: AutoTheta

Forecast Reliability
Score 55%
H-stat 2.65
Ljung-Box p 0.000
Jarque-Bera p 0.802
Excess Kurtosis -0.38
Attribute Value
Sector Healthcare
Debt to Equity Ratio 0.286
Market Cap 1,869,355,648
Forward P/E -9.08
Beta -2.58
Previous Name Pharvaris B.V.
Website https://pharvaris.com

As of April 11, 2026, 3:14 p.m. EDT: Options speculators are showing mixed signals. For near-term expirations, there is a notable concentration of puts around the 25.0 strike, indicating some bearish sentiment. However, for longer-dated options, there's a slight bullish tilt with calls at higher strikes, suggesting some optimism about potential price increases. The overall options activity seems to reflect cautious positioning with a focus on downside protection.


Info Dump

Attribute Value
52 Week Change 0.98482764
Address1 Grafenauweg 8
All Time High 42.86
All Time Low 1.77
Ask 28.91
Ask Size 1
Average Analyst Rating 1.4 - Strong Buy
Average Daily Volume10 Day 189,220
Average Daily Volume3 Month 159,624
Average Volume 159,624
Average Volume10Days 189,220
Beta -2.581
Bid 28.44
Bid Size 1
Book Value 4.894656
City Zug
Compensation As Of Epoch Date 1,767,139,200
Country Switzerland
Crypto Tradeable 0
Currency USD
Current Price 28.58
Current Ratio 10.106
Custom Price Alert Confidence HIGH
Date Short Interest 1,774,915,200
Day High 29.89
Day Low 28.49
Debt To Equity 0.286
Display Name Pharvaris
Earnings Timestamp 1,775,133,000
Earnings Timestamp End 1,778,589,000
Earnings Timestamp Start 1,778,589,000
Ebitda -169,633,776
Ebitda Margins 0.0
Enterprise To Ebitda -9.382
Enterprise Value 1,591,534,976
Eps Current Year -2.93891
Eps Forward -3.147468
Eps Trailing Twelve Months -3.5
Esg Populated 0
Exchange NMS
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 27.1367
Fifty Day Average Change 1.4433002
Fifty Day Average Change Percent 0.053186286
Fifty Two Week Change Percent 98.482765
Fifty Two Week High 29.89
Fifty Two Week High Change -1.3099995
Fifty Two Week High Change Percent -0.04382735
Fifty Two Week Low 13.81
Fifty Two Week Low Change 14.7699995
Fifty Two Week Low Change Percent 1.0695148
Fifty Two Week Range 13.81 - 29.89
Financial Currency EUR
First Trade Date Milliseconds 1,612,535,400,000
Float Shares 35,085,410
Forward Eps -3.147468
Forward P E -9.080315
Free Cashflow -79,089,728
Full Exchange Name NasdaqGS
Full Time Employees 129
Gmt Off Set Milliseconds -14,400,000
Gross Margins 0.0
Has Pre Post Market Data 1
Held Percent Insiders 0.051659998
Held Percent Institutions 0.90670997
Implied Shares Outstanding 65,407,822
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Ipo Expected Date 2,021-02-05
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,767,139,200
Long Business Summary Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Long Name Pharvaris N.V.
Market us_market
Market Cap 1,869,355,648
Market State POST
Max Age 86,400
Message Board Id finmb_402951024
Most Recent Quarter 1,767,139,200
Name Change Date 2,026-04-16
Net Income To Common -175,699,392
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 1,890,286,055
Number Of Analyst Opinions 13
Open 29.25
Operating Cashflow -137,073,632
Operating Margins 0.0
Payout Ratio 0.0
Phone 31 712036410
Post Market Change 0.0
Post Market Change Percent 0.0
Post Market Price 28.58
Post Market Time 1,776,456,605
Prev Name Pharvaris B.V.
Previous Close 28.78
Price Eps Current Year -9.724694
Price Hint 2
Price To Book 5.8390207
Profit Margins 0.0
Quick Ratio 10.006
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key strong_buy
Recommendation Mean 1.38462
Region US
Regular Market Change -0.20000076
Regular Market Change Percent -0.69492966
Regular Market Day High 29.89
Regular Market Day Low 28.49
Regular Market Day Range 28.49 - 29.89
Regular Market Open 29.25
Regular Market Previous Close 28.78
Regular Market Price 28.58
Regular Market Time 1,776,456,000
Regular Market Volume 148,412
Return On Assets -0.35808
Return On Equity -0.65190005
Sand P52 Week Change 0.36506534
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Shares Outstanding 65,407,822
Shares Percent Shares Out 0.0109
Shares Short 712,119
Shares Short Previous Month Date 1,772,150,400
Shares Short Prior Month 751,905
Short Name Pharvaris N.V.
Short Percent Of Float 0.0134000005
Short Ratio 4.08
Source Interval 15
Symbol PHVS
Target High Price 76.447395
Target Low Price 30.264767
Target Mean Price 46.77399
Target Median Price 42.82537
Total Cash 291,678,880
Total Cash Per Share 4.459
Total Debt 776,798
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -3.5
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 24.500525
Two Hundred Day Average Change 4.0794754
Two Hundred Day Average Change Percent 0.16650563
Type Disp Equity
Volume 148,412
Website https://pharvaris.com
Zip 6,300